Beltran, Himisha

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 2,157

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine

BRCA gene mutations in cancerGenetic factors in colorectal cancer

Cited by 1,680

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 1,559

Genomic correlates of clinical outcome in advanced prostate cancer

Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 1,372

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchNeuroblastoma Research and Treatments

Cited by 810

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 706

Cellular plasticity and the neuroendocrine phenotype in prostate cancer

Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology

Prostate Cancer Treatment and ResearchCancer Cells and Metastasis

Cited by 431

Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine

Prostate Cancer Treatment and ResearchLung Cancer Treatments and Mutations

Cited by 214

Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer

Bakht, M. K., & Beltran, H. (2025) · Nature Reviews Urology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 158

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 130

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology

Neuroendocrine Tumor Research AdvancesMonoclonal and Polyclonal Antibodies Research

Cited by 80

Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline

Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 64

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Beltran, H., Dowlati, A., Jain, P., Johnson, M. L., Sanborn, R. E., Thompson, J. R., Mamdani, H., Schenk, E. L., Aggarwal, R. R., Sankar, K., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 32